Business
Jazz Pharmaceuticals Presents 18 Abstracts in Sleep Medicine at SLEEP 2021
Jazz shares results from sleep medicine research and the development of novel therapeutic options for people living with sleep disorders DUBLIN, June 9, 2021
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"Jazz shares results from sleep medicine research and the development of novel therapeutic options for people living with sleep disorders\n\n\nDUBLIN, June 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021, the 35th annual meeting of the Associated Professional Sleep Societies (APSS) from June 10-13, 2021.\n\"Jazz continues to be committed to deepening our understanding of sleep disorders and delivering transformational medicines to those with lifelong and chronic sleep conditions,\" said Robert Iannone, M.D., M.S.C.E., executive vice president, research and development and chief medical officer of Jazz Pharmaceuticals. \"There remains a large unmet need for people living with sleep disorders, including narcolepsy and idiopathic hypersomnia, and we look forward to showcasing the latest research and results from our portfolio during SLEEP 2021 as we work to help people with sleep disorders live fuller lives.\"\nHighlights from Jazz at SLEEP 2021 will include the following presentations:\nA late-breaking abstract poster presentation on June 13 on a sub-group analysis of Xywav™ (calcium, magnesium, potassium and sodium oxybates) oral solution compared to placebo in adults with idiopathic hypersomnia with long sleep time (n=25) and without long sleep time (n=91), and the importance of treatment effects on those two groups Additional data results from the Phase 3, placebo-controlled, double-blind, randomized withdrawal study of Xywav in adults with idiopathic hypersomnia including an oral presentation of the correlation of the idiopathic hypersomnia severity scale score with other measures of sleep parameters Results from a real-world study of the cardiovascular burden of narcolepsy Data results from the titration and administration (START) study of Sunosi® (solriamfetol) in patients with narcolepsyXywav is not currently approved by regulatory authorities for the treatment of idiopathic hypersomnia.\nThe SLEEP 2021 presentations and exhibit hall are available for registered attendees through November 30, 2021 at www.sleepmeeting.org.\nFind a full list of Jazz-supported data below:\nXywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution Oral Presentati...